About |
President Trump signed an executive order fast-tracking federal review of ibogaine — a plant-derived psychedelic showing 80–90% addiction freedom rates in early studies. This is the most significant addiction treatment development in a generation. Here's what the science actually says.
"I sent President Trump some information. The text message came back: 'Sounds great. Do you want FDA approval? Let's do it.' It was literally that quick."
— JOE ROGAN, OVAL OFFICE, APRIL 18 2026
EXPLORE THE SCIENCE
STATE-BY-STATE PROGRESS
THE SCIENCE · THE POLICY · THE CAUTION
What you need to know about
ibogaine — without the hype.
We present ibogaine as what it is: a profoundly promising compound that demands rigorous science, not political speed. Here is the full picture — clinical evidence, federal action, known risks, and where research stands today.
????
What Is Ibogaine?
Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to West and Central Africa, where it has been used ceremonially for centuries. It is an atypical psychedelic that acts on multiple systems — opioid receptors, serotonin, glutamate, and dopamine pathways — simultaneously. Unlike conventional addiction medications, ibogaine appears to produce a neurobiological "reset" that interrupts both physical withdrawal and psychological craving in a single extended session lasting 12–36 hours.
Plant-Based
West Africa Origin
Multi-Receptor
Neurobiological Reset
????
The Clinical Evidence
Stanford Phase II (Jan 2026): 120 patients with treatment-resistant opioid use disorder — 71% abstinence at 6-month follow-up, dramatically exceeding standard MAT outcomes.
Stanford Veterans Trial (2024): 30 U.S. special operations veterans with TBI — magnesium-ibogaine protocol showed 88% average PTSD reduction, 87% depression reduction, 81% anxiety reduction at one-month post-treatment.
Joe Rogan's cited data: One dose — 80% addiction freedom rate. Two doses — over 90%. Bipartisan advocates including Rick Perry and Kyrsten Sinema have championed these results.
Stanford 2026
Phase II RCT
Veterans TBI
71% Abstinence
⚠️
Known Risks — Critical Context
Medical experts urge caution. Ibogaine causes QT prolongation — a dangerous slowing of heart electrical activity that can trigger fatal cardiac arrhythmias. Frederick Barrett of Johns Hopkins stated: "It is probably the most dangerous of all psychedelic-like compounds."
An FDA-approved trial begun in 1993 had its funding withdrawn over safety concerns. There have been documented cases of cardiac arrest and death associated with ibogaine internationally. Ibogaine currently remains Schedule I federally — meaning research has been severely limited, which is precisely why the executive order matters: to enable rigorous, monitored clinical science.
Cardiac Risk
QT Prolongation
Schedule I
Requires Monitoring
????️
Trump's Executive Order — What It Does
Signed April 18, 2026, with FDA Commissioner Marty Makary, HHS Secretary RFK Jr., Joe Rogan, and Marcus Luttrell present in the Oval Office. The order:
• Directs FDA to expedite review of certain psychedelics including ibogaine
• Opens a pathway under the Right to Try Act for patients with serious conditions
• Expands research funding and accelerates clinical trial pathways
• Signals a major policy shift from decades of Schedule I prohibition
Trump stated: "Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives."
Executive Order
Right to Try Act
FDA Fast-Track
April 2026
????
Rare Bipartisan Momentum
Ibogaine has achieved something virtually unprecedented in today's political climate: genuine bipartisan support.
Republicans: President Trump, Gov. Greg Abbott (Texas — $50M commitment), Rick Perry (Washington Post op-ed championing ibogaine for veterans)
Democrats: Former Sen. Kyrsten Sinema — long-standing advocate
Tennessee has joined Texas and Arizona in legalizing FDA-approved ibogaine research. CMS Administrator Dr. Mehmet Oz described the internal effort as a "rapid policy sprint." This is not a partisan issue — it's a humanitarian one.
Bipartisan
Texas $50M
3 States Active
Veterans Support
????
Where Research Stands: 2026
DemeRx Inc. holds the first FDA Investigational New Drug (IND) application for an ibogaine-class compound — an ibogaine derivative engineered to reduce cardiac QT risk while preserving anti-addictive efficacy. Phase II/III underway across multiple U.S. sites. Target: Phase III completion 2028, NDA submission 2029–2030.
FDA Breakthrough Therapy designation has been granted to two pharmaceutical companies developing safer ibogaine derivatives. Active trials now running in 12 U.S. states. The FDA has cleared the first U.S. ibogaine Phase I trial for alcohol use disorder.